CytoMed Therapeutics Limited (GDTC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CytoMed Therapeutics Limited announced the initiation of the ANGELICA Trial, a Phase I clinical study testing innovative off-the-shelf CAR-T cell therapy using gamma delta T cells against blood and solid tumors, with financial backing from Singapore’s National Medical Research Council. In a strategic move to bolster its cell therapy capabilities, CytoMed also acquired a licensed cord blood bank in Malaysia, enhancing its foray into cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd. This acquisition promises to expand the company’s portfolio in treatments for aging diseases and regenerative medicine.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.